Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

The invention relates to a composition based on a natural lignocellulose complex, a source of dietary fiber exhibiting antioxidant and adsorption properties and dihydromyrecitin or quercetin, which has hepatoprotective activity when used together due to multidirectional action. This combination can be used to reduce oxidative stress and its inducers in the blood and organs, as well as maintain the detoxification function of the liver and its restoration, contains dihydromyricetin or quercetin in an amount of 5 to 1000 mg and hydrolysed lignin in an amount of 50 mg to 5000 mg. Technical result: the combination has an unexpected synergistic effect aimed at reducing oxidative stress and its inducers, manifested in a decreased level of malondialdehyde and acetaldehyde in the blood and organs, as well as in a beneficial effect on liver function.

The invention relates to a composition based on a natural lignocellulose complex, a source of dietary fiber exhibiting antioxidant and adsorption properties and dihydromyrecitin or quercetin, which has hepatoprotective activity when used together due to multidirectional action. This combination can be used to reduce oxidative stress and its inducers in the blood and organs, as well as maintain the detoxification function of the liver and its restoration, contains dihydromyricetin or quercetin in an amount of 5 to 1000 mg and hydrolysed lignin in an amount of 50 mg to 5000 mg. Technical result: the combination has an unexpected synergistic effect aimed at reducing oxidative stress and its inducers, manifested in a decreased level of malondialdehyde and acetaldehyde in the blood and organs, as well as in a beneficial effect on liver function.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

Disclosed herein is a pharmaceutical composition for treating or preventing inflammatory diseases or arthritis, which includes 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition exhibits superior therapeutic efficacy against arthritis without any side effects such as toxicity, etc.

Provided herein are methods and dose packs for the monitoring of medication adherence. In one aspect, the dose pack comprises comprise a multiplicity of doses of an agent and a multiplicity of doses of a marker and be configured to isolate a pair of at least one of the multiplicity of doses of the agent and at least one of the multiplicity of doses of the marker for co-administration of the pair to the subject according to the dosing schedule. In another aspect, the method comprises obtaining a sample from the subject subsequent to the conclusion of a monitoring window and analyzing the sample for the presence or absence of a marker or a degradation product thereof.

Provided herein are methods and dose packs for the monitoring of medication adherence. In one aspect, the dose pack comprises comprise a multiplicity of doses of an agent and a multiplicity of doses of a marker and be configured to isolate a pair of at least one of the multiplicity of doses of the agent and at least one of the multiplicity of doses of the marker for co-administration of the pair to the subject according to the dosing schedule. In another aspect, the method comprises obtaining a sample from the subject subsequent to the conclusion of a monitoring window and analyzing the sample for the presence or absence of a marker or a degradation product thereof.

The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFB and as agonists (activators) of Nrf2. In particular, these compounds show dual activity and it has been discovered that these compounds are particularly useful in the treatment of certain cosmetic applications and in rejuvenating and beautifying skin and other keratinous tissue of a subject in need. Cosmetic compositions and methods of using said compositions in combination with other components are disclosed herein.